Date: 2013-04-03
Type of information: Production agreement
Compound: finished dosage forms of peptide-protein conjugate targeting Alzheimer’s disease
Company: Bachem (Switzerland) Axon Neuroscience (Slovak Republic)
Therapeutic area: Neurodegenerative diseases
Type agreement: manufacturing
production
Action mechanism:
Disease: Alzheimer’s disease
Details: Bachem and Axon Neurosciences have entered into a collaboration under which Bachem manufactures Axon’s investigational API and supplies it as a finished dosage form under Bachem’s Clinalfa® brand. Axon’s product targeting Alzheimer’s disease consists of a peptide-protein conjugate and will enter phase I clinical trials in Europe.
Financial terms:
Latest news:
